Parliamentary Panel Urges Swift India-US Trade Deal, Exemption for Generic Drugs and Smartphones

Rajya Sabha Committee Demands Speedy Trade Pact with US, Seeks Blanket Tariff Shield for Key Exports

A Parliamentary Standing Committee on Commerce has asked the Indian government to conclude the proposed Bilateral Trade Agreement (BTA) with the United States as quickly as possible while mandating that the deal includes blanket tariff exemptions for three strategic exports — generic medicines, critical minerals and smartphones — shielding them from any sudden American tariff hikes in the future.

The report, tabled in the Rajya Sabha on August 6, 2026 as the committee’s 200th evaluation, paints a picture of an unpredictable US tariff environment that has swung from a 50% levy reduction under a February 2026 interim pact to fresh Section 301 duties. The panel wants a “complete exemption” for the pinpointed products to create a stable trading corridor, even as broader tariff disputes continue to simmer. “Foreign taxes on Indian goods are changing too fast and unpredictably,” the report warns, arguing that a finalized BTA would give businesses in both countries the certainty they need.

Beyond immediate tariff defense, the committee called for a time‑bound roadmap under the Mission 500 initiative to boost goods and services trade, investment and cooperation in technology and supply‑chain resilience. It also recommended a dedicated “watch desk” under the Directorate General of Foreign Trade (DGFT) to monitor evolving US customs regulations and alert Indian exporters in real time. Other suggestions include technical and financial aid for micro, small and medium enterprises (MSMEs) to meet documentation hurdles, pre‑clearance mechanisms aligned with US FDA standards for pharmaceutical shipments, and targeted incentive schemes for traditional sectors like textiles and gems and jewellery.

The Indian trade surplus with the US reached $42.94 billion in 2025, yet India accounts for only 2.72% of US imports. The committee sees that vulnerability as a reason to double down on high‑value services — artificial intelligence, digital health, engineering research — and deeper cooperation in semiconductors, clean energy and critical minerals to strengthen domestic manufacturing and reduce import dependence.

The Strategic Calculus Behind Protecting Generic Drugs, Smartphones and Critical Minerals

Why Generic Medicines, Smartphones and Critical Minerals Were Chosen

The committee’s call for a blanket exemption is a precise, intentional targeting of sectors where India has proven manufacturing scale and a direct vulnerability to US tariffs. India supplies roughly 40% of the United States’ generic drug volume; a sudden tariff spike could disrupt pharmaceutical supply chains and squeeze margins for players like Sun Pharma and Dr. Reddy’s. Smartphone exports, driven largely by the government’s production‑linked incentive (PLI) scheme, have become a flagship manufacturing story, with Apple’s contract manufacturers now exporting billions of dollars worth of iPhones from India. That achievement is susceptible to a single adverse policy shift in Washington. Critical minerals — lithium, rare earths, cobalt — are at the heart of the clean‑energy transition and semiconductor manufacturing, where the US is trying to reduce its dependence on China. India, with its ambitious critical‑mineral exploration push, sees a strategic opening, but only if guaranteed market access is secured.

The Tariff Whiplash: From 50% Cuts to a New 10% Levy

The report lays bare the speed at which American trade policy can swing. In February 2026, an interim agreement slashed the US tariff on Indian goods from an average 50% to 18%, and Washington withdrew the extra 25% ad‑valorem duty that had been imposed over India’s imports of Russian crude oil. Weeks later, the US Supreme Court struck down reciprocal tariffs entirely, only for new measures to appear: a 10% across‑the‑board levy under Section 122 of the Trade Act, later replaced by action under Section 301. The committee’s push for a binding treaty with built‑in exemptions is an attempt to replace this “tariff‑of‑the‑month” climate with a legally anchored framework that cannot be easily overturned by executive fiat.

India’s Asymmetric Exposure: A 2.72% Share Problem

India runs a consistent trade surplus with the US ($42.94 billion in 2025), yet its exporters account for just 2.72% of all American imports. That makes them a negligible slice of US purchasing that can be targeted without immediate domestic blowback, a dynamic the committee wants to neutralise by locking in exemptions. The imbalance also means that even minor US tariff adjustments can produce outsized pain for specific Indian sectors, especially textiles and gems, which the report acknowledges need their own “market‑linked incentive schemes” to stay competitive.

The High-Value Services and Technology Pivot

Conscious that tariff fights can only go so far, the committee is urging a parallel push into AI, digital health, engineering research and semiconductor cooperation. This is not altruism: it aligns with Washington’s own TRUST framework for joint technology development and would embed Indian firms deeper into US‑centred supply chains, making them harder to penalize. The recommendation for joint FDA‑aligned testing facilities for pharma is cut from the same cloth — technical integration that turns a trade risk into a quality‑assurance asset.

What Indian Exporters and Policymakers Need to Take Away from the Trade Report

For Indian trade negotiators and exporters, the report flags concrete actions that could change the near‑term risk equation:

• Lock in tariff exemptions for the three priority sectors in the BTA draft. The committee wants a legally binding “complete exemption” for generic medicines, smartphones and critical minerals. Negotiators should treat this as a non‑negotiable from the parliamentary oversight body, strengthening their hand against US pressure on other fronts.
• Prepare to leverage the DGFT watch desk. Once operational, this desk will track US customs rule changes in real time. Exporters in heavily regulated sectors — pharmaceuticals, electronics, gems — should align their internal compliance teams to react to alerts on documentation, origin rules or new duty classifications before shipments are held at US ports.
• MSME exporters should explore the proposed technical and financial aid. The Ministry of MSME is likely to roll out assistance for proof‑of‑origin and other paperwork. Early engagement with industry bodies can ensure that small firms don’t lose out on the exemption benefits simply through administrative friction.
• Pharma companies must accelerate US‑FDA pre‑clearance readiness. The committee’s recommendation for joint testing facilities aligned with US standards is a clear signal that the government is willing to invest in infrastructure to support pharma exports. Companies that already meet FDA standards can push for faster implementation, while others should initiate gap analyses.
• Track the US political calendar and court actions. The report underscores how swiftly US tariff policy can change — from Supreme Court rulings to Section 301 investigations. Indian export strategists should link their near‑term planning to specific US administrative milestones, rather than relying on the assumption of a stable baseline.